New Approaches in the Management of Dementia-Related Psychosis (CME/CE Monograph)
Activity Description and Purpose
The prevalence of Alzheimer’s disease and related dementias is approximately 6 million, and is expected to increase to nearly 14 million by 2050. Along with a decline in cognition, driven by neurodegeneration, several behavioral and psychological symptoms of dementia are seen as the disease progresses. Hallucinations and delusions are among the more disruptive and burdensome symptoms for both caregivers and patients. These symptoms mimic other disorders and should always be investigated carefully to determine their root cause. In the case of dementia-related psychosis (DRP), it is thought that symptoms of psychosis arise from dysregulation of dopamine, glutamate, and serotonin in the brain of affected individuals. Best practices for assessment and treatment include thorough characterization of symptoms, investigation of root causes, and implementation of nonpharmacologic and pharmacologic treatment, as appropriate. The desired results of this activity are for clinicians to recognize psychosis as part of the neurodegenerative process in dementia and to treat symptoms effectively while maintaining the safety and quality of life of patients.
This educational activity is intended for psychiatrists and primary care providers, including physicians, physician assistants, nurse practitioners, and nurses, caring for patients with DRP, including those practicing in the long-term care setting.
After completing this activity, participants will be better able to:
- Identify psychotic symptoms among patients with dementia in routine practice
- Describe the pathogenesis of psychosis in the context of dementia
- Discuss best practices for assessment of psychosis in patients with dementia
Marc E. Agronin, MD (Chair)
Senior Vice President for Behavioral Health
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Jeffrey L. Cummings, MD, ScD
Director, Chambers-Grundy Center for Transformative Neuroscience
Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Director, Center for Neurodegeneration and Translational Neuroscience
Director Emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada
Zaldy S. Tan, MD, MPH
Director, Memory and Aging Program
Cedars-Sinai Health System
Medical Director, Jona Goldrich Center for Alzheimer’s and Memory Disorders
Cedars-Sinai Medical Center
Los Angeles, California
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Marc E. Agronin, MD, has no relevant commercial relationships to disclose.
Jeffrey L. Cummings, MD, ScD, is an owner of CNS Innovations; a consultant for ACADIA Pharmaceuticals Inc, Actinogen, AgeneBio, Inc, Alkahest, Inc, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Idec, Cassava Sciences, Inc, Cerecin Inc, Cerevel Therapeutics, LLC, Cognoptix Inc, Cortexyme, Cytox, EIP Pharma, Inc, Eisai Inc, F. Hoffmann-La Roche Ltd, Foresight Pharmaceuticals, Green Valley Inc, Grifols, S.A., Hisun USA, Inc, Karuna Therapeutics, Otsuka America Pharmaceutical, Inc, reMYND, Resverlogix, Samumed, LLC, Samus Therapeutics, Inc, Signant Health, Sunovion Pharmaceuticals Inc, Suven Life Sciences Limited, and United Neuroscience; and has ownership interest in Adamas Pharmaceuticals, Inc, Annovis Bio, Inc, BioAsis Technologies, Inc, MedAvante-ProPhase, Inc, and United Neuroscience. He reports his spouse is an owner of CNS Innovations LLC.
Zaldy S. Tan, MD, MPH, has no relevant commercial relationships to disclose.
Peer Reviewer Disclosure
Rita Khoury, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 228
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation